A stark epidemiological reality underscores the urgency of vaccine development efforts: zero licensed vaccines currently exist for Lassa fever, despite the disease affecting between 100,000 and 300,000 people annually across West Africa. This gap in vaccine coverage stands in sharp contrast to other major hemorrhagic fevers, where licensed vaccines for yellow fever and Ebola are available, while Marburg remains in clinical trials.
The recently completed phase 1 trial of a novel dual Lassa-rabies vaccine represents meaningful progress toward addressing this unmet medical need. Researchers at the University of Maryland’s Center for Vaccine Development and Global Health reported that the candidate vaccine demonstrated safety and generated appropriate immune responses against both Lassa fever virus and rabies virus in healthy adult volunteers. These preliminary findings suggest a potential pathway to filling this critical gap in infectious disease prevention.
Read the full article on GMJ Newsroom.
Was this article helpful?
